Open access
Open access
Powered by Google Translator Translator

Infectious Diseases (all articles)

Breakthrough infections generate ‘super immunity’ to COVID-19, study suggests.

17 Dec, 2021 | 09:47h | UTC

News Release: Breakthrough infections generate ‘super immunity’ to COVID-19, study suggests – Oregon Health & Science University

Original Study: Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection – JAMA

 

Opinion: COVID-19 vaccine strategies must focus on severe disease and global equity.

17 Dec, 2021 | 09:45h | UTC

COVID-19 vaccine strategies must focus on severe disease and global equity – The Lancet

 

How COVID vaccines shaped 2021 in eight powerful charts.

17 Dec, 2021 | 09:44h | UTC

How COVID vaccines shaped 2021 in eight powerful charts – Nature

 

Guideline: Prevention, diagnosis, and management of post-surgical mediastinitis in adults.

17 Dec, 2021 | 08:41h | UTC

Prevention, Diagnosis and Management of Post-Surgical Mediastinitis in Adults Consensus Guidelines of the Spanish Society of Cardiovascular Infections (SEICAV), the Spanish Society of Thoracic and Cardiovascular Surgery (SECTCV) and the Biomedical Research Centre Network for Respiratory Diseases (CIBERES) – Journal of Clinical Medicine

 

Review uncovers weak COVID clinical practice guidelines.

16 Dec, 2021 | 10:31h | UTC

Review uncovers weak COVID clinical practice guidelines – CIDRAP

Original Study: Adherence of Clinical Practice Guidelines for Pharmacologic Treatments of Hospitalized Patients With COVID-19 to Trustworthy Standards: A Systematic Review – JAMA Network Open

 

Commentary on Twitter

 

Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021.

17 Dec, 2021 | 08:36h | UTC

Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021 – IDStewardship

 

Commentary on Twitter

 

Modeling COVID-19 mortality across 44 Countries: Face covering may reduce deaths.

16 Dec, 2021 | 10:33h | UTC

Modeling COVID-19 Mortality Across 44 Countries: Face Covering May Reduce Deaths – American Journal of Preventive Medicine

Commentary: Mask laws could prevent unnecessary COVID-19 deaths, study shows – News Medical

 

Autoimmune encephalitis after SARS-CoV-2 infection: case frequency, findings, and outcomes.

16 Dec, 2021 | 09:47h | UTC

Autoimmune Encephalitis After SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes – Neurology

 

Commentary on Twitter

 

Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”.

16 Dec, 2021 | 09:52h | UTC

Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature

Related:

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Opinion: Unequal global vaccine coverage is at the heart of the current covid-19 crisis.

16 Dec, 2021 | 09:50h | UTC

Unequal global vaccine coverage is at the heart of the current covid-19 crisis – The BMJ

 

Recommendations for antibiotic selection for severe nosocomial infections.

16 Dec, 2021 | 09:40h | UTC

Recommendations for antibiotic selection for severe nosocomial infections – Revista Espanola de Quimioterapia

 

T Cells might be our bodies’ best shot against Omicron.

16 Dec, 2021 | 09:45h | UTC

T Cells Might Be Our Bodies’ Best Shot Against Omicron – The Atlantic

 

Antibiotics in critically ill children—a narrative review on different aspects of a rational approach.

16 Dec, 2021 | 08:53h | UTC

Antibiotics in critically ill children—a narrative review on different aspects of a rational approach – Pediatric Research

 

M-A: Global percentage of asymptomatic SARS-CoV-2 infections around 40%.

15 Dec, 2021 | 08:47h | UTC

Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis – JAMA Network Open

Commentary: ~40 Percent With Confirmed COVID-19 Are Asymptomatic – HealthDay

 

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

15 Dec, 2021 | 08:43h | UTC

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection – Nature Medicine

News release: COVID-19 infection, more likely than vaccines, to cause rare cardiovascular complications – University of Oxford

 

Commentaries on Twitter

 

[Press release – not published yet] Pfizer’s Covid pill remains 89% effective for reducing the risk of hospitalization or death in final analysis.

15 Dec, 2021 | 08:46h | UTC

News release: Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel Covid-19 oral antiviral treatment candidate in reducing risk of hospitalization or death

Commentaries:

Pfizer’s Covid pill remains 89% effective in final analysis, company says – STAT

Pfizer confirms COVID pill’s results, potency versus omicron – Associated Press

Related:

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

 

Commentary on Twitter (thread – click for more)

 

Rapidly spreading Omicron is now in 77 countries and WHO warns against assuming its effects are mild.

15 Dec, 2021 | 08:39h | UTC

Rapidly Spreading Omicron is Now in 77 Countries and WHO Warns Against Assuming its Effects are Mild – Health Policy Watch

 

Study suggests COVID-19 certificates may boost vaccine uptake in countries with below average coverage.

15 Dec, 2021 | 08:41h | UTC

News Release: COVID-19 certificates may boost vaccine uptake in countries with below average coverage – University of Oxford

Original Study: The effect of mandatory COVID-19 certificates on vaccine uptake: synthetic-control modelling of six countries – The Lancet Public Health

 

Commentary on Twitter

https://twitter.com/ruettenauer/status/1470675353937063937

 

COVID-19 in 2022: controlling the pandemic is within our grasp.

15 Dec, 2021 | 08:36h | UTC

COVID-19 in 2022: controlling the pandemic is within our grasp – Nature Medicine

 

Commentaries on Twitter

 

Expert consensus and practical guidance: A global perspective on improving patient care in uncomplicated urinary tract infection.

15 Dec, 2021 | 08:33h | UTC

A global perspective on improving patient care in uncomplicated urinary tract infection: Expert consensus and practical guidance – Journal of Global Antimicrobial Resistance

 

[Not published yet] Initial data from South Africa showed vaccine protection vs. Omicron infection may drop to 30% but does cut severe disease.

15 Dec, 2021 | 08:38h | UTC

Vaccine protection vs. omicron infection may drop to 30% but does cut severe disease – NPR

See also: South Africa Omicron study finds drop in vaccine protection, fewer hospitalized – CIDRAP

 

Review: Diagnosis and management of acute appendicitis in adults.

15 Dec, 2021 | 08:28h | UTC

Diagnosis and Management of Acute Appendicitis in Adults: A Review – JAMA (free for a limited period)

Author Interview: Current Management of Acute Appendicitis: Antibiotics or Surgical Intervention

Commentary: Antibiotics can be first-line therapy for uncomplicated appendicitis cases – Duke University Medical Center

 

Proposed subtypes of long-Covid and their respective potential therapies.

14 Dec, 2021 | 09:49h | UTC

Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies – Reviews in Medical Virology

Related:

EuGMS Guidance: Management of post-acute COVID-19 patients in geriatric rehabilitation.

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

 

Omicron: WHO updated technical brief and priority actions.

14 Dec, 2021 | 09:50h | UTC

Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States – World Health Organization

 

Commentary on Twitter (thread – click for more)

 

Infectious diseases learning pearls from inpatient ID consults.

15 Dec, 2021 | 08:22h | UTC

ID Learning Units from Inpatient ID Consults – HIV and ID Observations

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.